News and research before you hear from CNBC and others. Claim your free 1-week trial of StreetInsider Premium here. Lexaria has just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged 40 to 70 years with measured high blood pressure, stage 1 and 2 hypertension HYPER-H21-4, the study Lexaria’s most ambitious hypertension clinical to date, it builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021. It explores the use of the patented DehydraTECH(TM) technology of the company in the potential treatment of hypertension. Lexaria is confident that the additional data sets collected throughout the study will lead to additional applications for DehydraTECH while providing valuable additional information on the long-term health benefits of this compound that otherwise are not detected.
In November 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most ambitious hypertension study to date, HYPER-H21-4. The purpose of the study, according to Lexaria’s Chief Executive Officer (“CEO”), Chris Bunka, was to “Support the Company’s objectives related to seeking regulatory approvals for DehydraTECH-CBD for a potential as a treatment for high blood pressure.” (https://cnw.fm/8fXrT).
At year-end, Lexaria received approval from the Independent Review Board (“IRB”) ahead of schedule, marking a major milestone for the company. It would set the stage for the start of the study in 2022 while allowing Lexaria to explore the full potential of its…
NOTE TO INVESTORS: The latest news and updates related to LEXX are available from the company newsroom at
About CBDWire
CBDWire (CBDW) is a specialist information provider focused on (1) reporting CBD-related news and updates, (2) publishing CBDNewsBreaks designed to keep investors up to date with the latest and greatest developments in the CBD market, (3) refine and improve corporate press releases, (4) provide end-to-end distribution and social media services to partner-clients and (5) build an effective company. communication solutions based on the unique requirements of CBD companies. CBDW is uniquely situated in the growing CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expanding target audience of investors, consumers and industry media. Our outreach network of over 5,000 downstream distribution points allows us to provide unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the broader cannabis space. CBDWire (CBDW) is where CBD news, content and information come together.
To receive instant SMS alerts, text CBDWire to 21000 (US cell phones only)
Please see the full terms of use and disclaimers on the CBDWire website that apply to all content provided by CBDW, whenever posted or reposted:
Have questions or are you interested in working with CNW? Ask our editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]
CBDWire is part of InvestorBrandNetwork.